Hubbry Logo
Sweat testSweat testMain
Open search
Sweat test
Community hub
Sweat test
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Sweat test
Sweat test
Sweat test
View on Wikipedia
from Wikipedia
Sweat test
Purposemeasures concentration of chloride

The sweat test measures the concentration of chloride that is excreted in sweat. It is used to screen for cystic fibrosis (CF).[1] Due to defective chloride channels (CFTR), the concentration of chloride in sweat is elevated in individuals with CF.

Background

[edit]

Cystic fibrosis is caused by defects in a protein found in many tissues, including the airways and the sweat glands.[1] As a result, these tissues do not work properly. Sweat testing makes use of the fact that cystic fibrosis patients have defective sweat glands.[2]

Sweat glands produce sweat through a well understood process of secretion and reabsorption of sodium chloride (salt). Secretion entails the movement of salt and water from sweat gland cells into the sweat duct. Reabsorption occurs in the duct with the movement of salt from the sweat back into sweat duct cells. What remains is sweat, a salt solution with a relatively finely tuned concentration of sodium and chloride.[citation needed]

For normal salt reabsorption to occur, individual ions of sodium and chloride must be taken from the sweat and moved back into cells of the sweat duct. These ions are moved by transporters called ion channels. In the case of sodium, there is a sodium channel; for chloride, there is a chloride channel called CFTR. For sweat to be produced with the proper concentrations of sodium and chloride, sodium channels and chloride channels (CFTRs) must work properly.[citation needed]

In cystic fibrosis, the CFTR chloride channel is defective, and does not allow chloride to be reabsorbed into sweat duct cells. Consequently, more sodium stays in the duct, and more chloride remains in the sweat. The concentration of chloride in sweat is therefore elevated in individuals with cystic fibrosis.[citation needed]

The concentration of sodium in sweat is also elevated in cystic fibrosis. Unlike CFTR chloride channels, sodium channels behave perfectly normally in cystic fibrosis. However, in order for the secretion to be electrically neutral, positively charged sodium cations remain in the sweat along with the negatively charged chloride anions. In this way, the chloride anions are said to "trap" the sodium cations.[citation needed]

Method

[edit]

Sweating is induced by pilocarpine iontophoresis.[3] At the test site, an electrode is placed over gauze containing pilocarpine and electrolyte solution that will not interfere with the sodium and chloride measurement. A second electrode (without pilocarpine) will be placed at another site and a mild electric current will draw the pilocarpine into the skin where it stimulates the sweat glands.

The test site is carefully cleaned and dried, then a piece of preweighed filter paper is placed over the test site and covered with parafilm to prevent evaporation. Specialized collection devices may also be used. Sweat is collected for 30 minutes. The filter paper is retrieved and weighed to determine the weight of sweat collected. Several laboratory methods are then used to determine the sodium and chloride concentrations.[citation needed]

Before this method of inducing sweat was developed, the method was to place the entire person to be tested in a hemispherical chamber and slowly raise the humidity and temperature of the air inside.[4]

Results

[edit]

Reference ranges

[edit]

For infants up to and including 6 months of age, a chloride level of:

  • Equal to or less than 29 mmol/L = CF is very unlikely
  • 30 – 59 mmol/L = intermediate means that CF is possible
  • Greater than or equal to 60 mmol/L = CF is likely to be diagnosed

For people older than 6 months of age, a chloride level of:

  • Equal to or less than 39 mmol/L = CF is very unlikely
  • 40 – 59 mmol/L = intermediate means that CF is possible
  • Greater than or equal to 60 mmol/L = CF is likely to be diagnosed

[5][6]

Interpretation

[edit]

Two reliable positive results on two separate days is diagnostic for CF. Because of the existence of milder variants, borderline or even near-borderline negative results may be used to diagnose CF. Clinical presentation, family history and patient age must be considered to interpret the results. Highly discordant sodium and chloride values may indicate technical errors.[citation needed]

Sources of error

[edit]

Technical errors, insufficient sample, evaporation, contamination, dehydration, mineralocorticoid hormone therapy, and skin rash on the tested area may produce incorrect results. Positive test results may also be caused by malnutrition, adrenal insufficiency, glycogen storage diseases, hypothyroidism, hypoparathyroidism, nephrogenic diabetes insipidus, G6PD deficiency or ectodermal dysplasia.[citation needed]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Sweat test

View on Grokipedia
from Grokipedia
The sweat test, also known as the sweat test, is a diagnostic procedure that measures the concentration of in sweat to identify (CF), an inherited disorder caused by mutations in the CFTR gene that impair transport across cell membranes. It is the gold standard for confirming CF , particularly following positive or in individuals presenting with symptoms such as recurrent lung infections, , or salty-tasting skin. Sweat levels are also used to monitor response to CFTR modulator therapies. The test is noninvasive, painless, and recommended for infants as young as two weeks old, with results guiding early intervention to improve long-term outcomes. The discovery of elevated sweat chloride levels in CF patients dates back to 1953, when researcher Paul di Sant'Agnese observed excessive saltiness in the sweat of affected children during a , linking it to the disease's . This led to the development of the standardized quantitative pilocarpine iontophoresis test (QPIT) in 1959 by Gibson and Cooke, which remains the basis for modern sweat testing protocols. Over the decades, the test has evolved alongside advancements in CF understanding, including the identification of the CFTR gene in 1989 and more than 2,000 associated mutations, but it continues to serve as the primary confirmatory tool due to its high . Performed at accredited centers, such as those recognized by the Foundation, the sweat test ensures reliable results and is often combined with for comprehensive diagnosis. As of 2025, emerging wearable technologies are being developed to facilitate continuous sweat monitoring.

Overview

Definition and Purpose

The sweat test is a non-invasive diagnostic procedure that measures the concentration of , and sometimes sodium, in sweat induced through , a method that uses a mild electrical current to deliver the pilocarpine stimulant to the skin. This test targets the eccrine sweat glands, which are stimulated to produce a localized sample of sweat for . The primary purpose of the sweat test is to diagnose (CF) by identifying elevated levels of in the sweat, which signal dysfunction in the (CFTR) protein. In CF, mutations in the CFTR impair the protein's ability to regulate across epithelial cell membranes, leading to abnormal electrolyte retention in sweat. Normally, sweat produced by eccrine glands has low electrolyte content due to CFTR-mediated of in the sweat ducts, but this process is defective in CF, resulting in higher concentrations. Established as the gold standard for CF diagnosis since its development in the 1950s, the sweat test demonstrates over 90% when conducted according to standardized protocols. This reliability stems from its direct assessment of CFTR function through sweat levels, making it a cornerstone for confirming CF in individuals with suggestive symptoms or positive results.

Historical Background

The sweat test originated from observations made in 1953 by Paul A. di Sant'Agnese and colleagues at , who noted elevated salt concentrations in the sweat of children with (CF) during a severe in that caused and fatalities among affected infants. This finding, published in the journal , marked the first recognition of sweat electrolyte abnormalities as a hallmark of CF , shifting diagnostic approaches from clinical symptoms alone to biochemical markers. A pivotal advancement came in 1959 with the development of the quantitative iontophoresis technique by Lewis E. Gibson and Robert E. Cooke, which standardized sweat stimulation using a mild electrical current to deliver and subsequent measurement via chemical analysis. This method, detailed in their seminal paper, addressed inconsistencies in earlier qualitative assessments and established the foundation for reliable CF diagnosis, requiring at least 75 mg of sweat for accurate quantification. In the , sweat conductivity testing emerged as a practical screening alternative to direct measurement, leveraging the electrical conductivity of sweat electrolytes to provide rapid results with equipment like early analyzers, though it was initially viewed as complementary rather than diagnostic. efforts intensified in subsequent decades; the Foundation (CFF) issued comprehensive guidelines in 2007 to ensure , including requirements for accredited laboratories and repeat testing protocols. These were updated in 2017 to incorporate refined diagnostic thresholds and address variability in testing. Concurrently, the European Society contributed to global harmonization by defining protocols in its standards of care, emphasizing minimum sweat volumes and analytical precision to reduce inter-laboratory discrepancies. These guidelines have continued to evolve, with the ECFS issuing updated standards of care guidance for sweat testing in 2022 and the CFF publishing evidence-based guidelines for CF diagnosis in 2024 that reaffirm the test's central role.

Clinical Significance

Role in Cystic Fibrosis Diagnosis

The sweat test serves as the gold standard confirmatory test for (CF) diagnosis, measuring sweat concentration to assess (CFTR) function. According to diagnostic criteria established by the Foundation (CFF), a sweat level greater than 60 mmol/L in infants and children confirms the diagnosis of CF, while levels below 30 mmol/L make CF unlikely; intermediate values between 30 and 59 mmol/L indicate inconclusive results necessitating further evaluation, such as CFTR . Integration into clinical guidelines emphasizes the sweat test's role within a multi-step diagnostic pathway. The CFF and international consensus panels recommend it as the primary confirmatory test following a positive (NBS) or clinical suspicion of CF, often in combination with immunoreactive (IRT) levels from NBS and genetic analysis to enhance diagnostic precision. For instance, it is advised to perform the test on newborns after 10 days of age if NBS is positive, with repeat testing required for borderline results to resolve ambiguity. This approach aligns with expert recommendations from 32 specialists across 10 countries, achieving 80-100% agreement on protocols. Evidence supports the sweat test's high reliability, with studies indicating approximately 98% accuracy in detecting CF among affected individuals when properly conducted, particularly when combined with IRT screening to minimize false positives from NBS. False negatives are rare but can occur in cases of atypical CF with milder CFTR dysfunction, underscoring the need for clinical correlation and genetic confirmation in equivocal scenarios. Globally, the sweat test accounts for the majority of CF diagnoses, making it an essential tool for diagnosis in low- and middle-income countries where access to genetic testing is limited.

Other Diagnostic Applications

Beyond its primary role in cystic fibrosis diagnosis, the sweat test has been explored for evaluating other conditions involving imbalances. In congenital chloride diarrhea (CCD), a rare autosomal recessive disorder characterized by lifelong watery due to defective chloride-bicarbonate exchange in the and colon, sweat levels are typically normal or low, helping to differentiate it from where levels are elevated. This distinction is crucial, as initial presentations of CCD can mimic with and , but normal sweat (e.g., 27 mEq/L) alongside high fecal supports the CCD diagnosis. Similarly, in type 1 (PHA1), a condition of resistance leading to salt wasting, , and , sweat levels are often elevated (e.g., >60 mmol/L), mimicking and prompting confirmatory or aldosterone measurements. In research settings, the serves as a for assessing the efficacy of CFTR modulators in clinical trials for patients. Multiple phase III trials have demonstrated that drugs like and reduce sweat chloride concentrations by 20-50 mmol/L, correlating with improved lung function and providing a quantifiable measure of CFTR channel restoration. However, the sweat test's application to non-cystic fibrosis conditions is limited by a lack of and reduced diagnostic sensitivity, often necessitating complementary tests such as serum electrolytes or genetic . For adrenal disorders like , while elevated sweat chloride occurs in many cases, the test's reliability is lower than for (with variable reporting of false negatives in treated patients), and it is not validated as a standalone diagnostic tool. The Cystic Fibrosis Foundation guidelines emphasize the sweat test primarily for evaluation and advise against its routine use for other diagnoses due to these constraints. Emerging post-2020 has investigated wearable sweat sensors for early detection of metabolic disorders, such as or , by continuously monitoring biomarkers like glucose, lactate, and electrolytes in real-time. Pilot studies have shown these devices can detect sweat glucose fluctuations correlating with blood levels in diabetic models, though clinical validation remains pending, with challenges in sweat rate variability and sensor accuracy. As of 2025, ongoing includes wearable sensors for monitoring progression and via sweat biomarkers like glucose, though full clinical validation for diagnostic use is still emerging. Overall, outside , the sweat test functions mainly as a tool rather than a standard clinical .

Procedure

Patient Preparation

The sweat test is suitable for patients older than 48 hours, with a recommendation for term infants to be at least 2 weeks old and weighing more than 2 kg to ensure adequate sweat production and minimize false positives due to transient elevations in the early neonatal period. For newborns with a positive screening, testing is ideally performed by the end of the neonatal period but can be delayed if the infant is unstable or under 10 days old. Contraindications include acute skin conditions such as infections, , severe eczema, burns, or non-intact at potential collection sites on the or , as these may contaminate the sample or cause irritation during stimulation. The test should also be postponed in cases of , acute , fever, , or if the patient is receiving supplemental oxygen via an open delivery system, to avoid unreliable results from altered hydration status. Certain medications, such as topiramate or 9-alpha , may interfere and warrant consultation with a pathologist before proceeding. Pre-test instructions emphasize ensuring the patient's skin is clean and dry at the collection site, with no application of lotions, oils, or creams for at least 24 hours prior to avoid interference with sweat induction. Hydration is encouraged by advising intake of 0.5 to 2.0 liters of non-caffeinated fluids the day before, depending on age, while no fasting or dietary restrictions are required, and normal meals and medications can continue. Patients should be informed that the procedure may cause mild tingling or warmth from iontophoresis but is generally well-tolerated. For special populations like neonates and infants under 3 months, preparation involves using smaller electrodes and ensuring the testing environment keeps the warm to promote sweat production, with procedures performed by experienced staff to reduce the risk of insufficient sample volume. In individuals with eczema, site selection avoids irritated areas. A minimum sweat weight of 75 mg is required for valid analysis using or methods over a collection area of at least 4 square inches within 30 minutes, as inadequate volume can compromise result reliability and necessitate repeat testing. Proper preparation directly influences achieving this threshold, particularly in young infants where insufficient sweat rates are more common.

Sweat Collection Method

The sweat collection method for the sweat test, known as quantitative (QPIT), begins with the stimulation of localized sweat production on the skin, typically the distal , using a agent delivered via a mild electrical current. nitrate, at a concentration of 2-5 g/L, is applied to the skin surface through or saturated with the solution and placed within a stimulating ; a counter soaked in deionized is positioned nearby to complete the circuit. is then performed using a battery-powered device that delivers a of 1.5-4 mA for 3-5 minutes, ensuring the current path avoids the heart and the procedure remains painless for the patient. This step induces secretion in a defined area, usually 2 x 2 inches, without systemic effects. Following , sweat is collected from the same site to prevent and ensure accurate measurement of concentration. The preferred apparatus includes the Macroduct coil system, a disposable tube with a hygrometric coil that absorbs and measures sweat volume directly, requiring a minimum of 15 μL collected over 20-30 minutes. Alternatively, or (pre-weighed and chloride-free) can be used, folded over the stimulated area and covered with or aluminum foil to minimize evaporation, with a minimum collection of 75 mg in 30 minutes. Throughout collection, the site is kept clean and isolated from external moisture, such as rain or lotions, and the skin is dried gently with if needed to avoid dilution. The process emphasizes single-site collection per test to maintain consistency in sweat rate. Older alternative methods, such as the Gibson-Cooke technique using pads for collection after stimulation, are less preferred due to higher risks of and variable absorption but may still be employed in resource-limited settings. For rapid screening, particularly in newborns, sweat conductivity measurement via devices like the Wescor Macroduct or Nanoduct analyzer can be used, which assesses levels directly on a small sample (3-15 μL) without full chemical analysis. Quality controls are integral to ensure sample validity, including verification of an adequate sweat rate of at least 1 g/m²/min (equivalent to 1-2 mg/min for the typical collection area), with collections discarded as quantity not sufficient (QNS) if below the minimum volume after 30 minutes. Bilateral testing from both arms or legs may be performed if one site yields insufficient sweat, but results must align within acceptable limits. The entire procedure, from stimulation to collection, typically lasts 45-60 minutes and must be conducted by trained laboratory technicians in a controlled clinical environment to adhere to standards like those from the Clinical and Laboratory Standards Institute (CLSI).

Analysis and Interpretation

Reference Ranges

The reference ranges for sweat concentration in the sweat are standardized to aid in the of , with serving as the primary analyte due to its direct reflection of CFTR function. According to the Cystic Fibrosis Foundation's 2017 consensus guidelines, which remain current as of 2024, a sweat level below 30 mmol/L is classified as normal, indicating is unlikely; levels between 30 and 59 mmol/L are intermediate, warranting additional genetic or functional testing; and levels of 60 mmol/L or higher are positive, supporting a of when corroborated by clinical findings. Age-related adjustments to reference ranges account for maturational changes in sweat gland function. Testing is generally deferred for premature infants until the infant reaches at least 36 weeks postmenstrual age and 2 kg body weight to ensure reliable collection; standard ranges apply thereafter. Ranges stabilize after 6 months of age, aligning with adult standards. Quantitative analysis of sweat electrolytes employs coulometric titration as the gold standard method, which precisely measures via silver generation and endpoint detection. Ion-selective electrodes provide an acceptable alternative for chloride determination, offering rapid results with comparable accuracy. These reference ranges derive from extensive cohorts analyzed in studies spanning the 1980s to 2010s, encompassing over 10,000 patients and non-patients to establish diagnostic thresholds with high . Updates in the 2017 guidelines incorporate insights from CFTR genetic subtypes, refining interpretation for intermediate results in carriers or atypical cases without altering core numerical cutoffs.

Result Interpretation

Sweat chloride concentrations exceeding 60 mmol/L are considered positive and strongly indicative of (CF), prompting confirmatory actions such as CFTR gene sequencing to identify two CF-causing , which together establish the . Guidelines recommend verifying positive results with a second sweat test on a separate occasion or through independent methods like genetic analysis to ensure accuracy. Intermediate results, ranging from 30 to 59 mmol/L, occur in some patients with genetically confirmed CF and necessitate further evaluation, including repeat sweat testing within 1–2 months or alternative assessments such as nasal potential difference measurement. Approximately 15% of sweat tests yield intermediate values, often leading to repeats, and these cases may represent cystic fibrosis transmembrane conductance regulator-related metabolic syndrome (CRMS) or CF with milder presentations. Results below 30 mmol/L are negative and typically rule out CF, though ongoing clinical monitoring is advised if symptoms or family history raise suspicion. Sweat test results are integrated with for comprehensive ; for instance, the presence of two CFTR mutations confirms CF even if sweat is intermediate, while one mutation with intermediate levels may indicate carrier status or CF requiring multidisciplinary follow-up. This combined approach is particularly valuable in diagnosing or late-onset CF presentations.

Sources of Error

Technical errors in sweat testing primarily arise during sample collection and can significantly compromise result accuracy. Insufficient sweat , defined as less than 75 mg for gauze methods or 15 µL for capillary collection, is a common issue, often resulting from patient dehydration, which reduces sweat production and leads to quantity not sufficient (QNS) outcomes, particularly in infants under 6 months where rates can reach 20-25%. may occur from improper skin cleaning or use of saline, introducing extraneous chloride and elevating measured concentrations, especially if collection exceeds 30 minutes or sites with inflammation are selected. Biological factors also contribute to variability and potential inaccuracies. Conditions such as can dilute sweat electrolytes by altering absorption into the skin, potentially leading to falsely low levels, while or eczema at the stimulation site may increase concentrations through local or impaired . Seasonal variations affect sweat rates, with higher production and potentially altered levels in summer due to increased hydration demands or environmental heat, particularly influencing results in patients. Laboratory issues further introduce risks, including electrode malfunctions that cause uneven pilocarpine stimulation and inconsistent sweat induction across sites. Calibration errors in chloridometers or ion-selective analyzers can result in drifts of up to ±5 mmol/L, often from pipetting inaccuracies or inadequate quality controls, leading to biased chloride measurements. To mitigate these errors, the Cystic Fibrosis Foundation recommends quality assurance programs, including regular equipment inspections, duplicate bilateral collections, and adherence to CLSI guidelines for prompt analysis to minimize evaporation. Operator training, requiring 3-5 supervised tests without QNS, and participation in proficiency testing like CAP surveys are essential, with accredited labs achieving invalidation rates below 5% for patients over 3 months. False positives from laboratory errors occur in approximately 1-2% of cases, often due to contamination or analytical bias, while false negatives are more prevalent in pancreatic-sufficient cystic fibrosis, affecting up to 15% with borderline or normal results that may be misinterpreted.

References

  1. https://www.ncbi.nlm.nih.gov/books/NBK547728/
  2. https://medlineplus.gov/lab-tests/sweat-test-for-cystic-fibrosis/
  3. https://www.sciencedirect.com/science/article/pii/S1569199321000345
  4. https://www.cff.org/intro-cf/sweat-test
  5. https://www.mayoclinic.org/diseases-conditions/cystic-fibrosis/diagnosis-treatment/drc-20353706
  6. https://news.feinberg.northwestern.edu/2025/08/18/new-wireless-sweat-patch-may-improve-cystic-fibrosis-treatment/
  7. https://www.frontiersin.org/journals/pediatrics/articles/10.3389/fped.2021.649904/full
  8. https://hopkinscf.org/knowledge/cftr/
  9. https://pubmed.ncbi.nlm.nih.gov/13633369/
  10. https://www.cff.org/medical-professionals/sweat-test-clinical-care-guidelines
  11. https://pmc.ncbi.nlm.nih.gov/articles/PMC5474375/
  12. https://www.nationaljewish.org/conditions/cf/history
  13. https://pubmed.ncbi.nlm.nih.gov/13111855/
  14. https://publications.aap.org/pediatrics/article/102/Supplement_1/230/28087/Test-for-the-Concentration-of-Electrolytes-in
  15. https://onlinelibrary.wiley.com/doi/10.1002/ppul.22945
  16. https://www.jpeds.com/article/S0022-3476(07)00238-7/fulltext
  17. https://www.jpeds.com/article/S0022-3476(16)31048-4/fulltext
  18. https://www.ecfs.eu/sites/default/files/standards-of-care-files/All%20statements.pdf
  19. https://www.cysticfibrosisjournal.com/article/S1569-1993(22)00025-X/fulltext
  20. https://publications.aap.org/pediatrics/article/153/5/e2023064657/197079/Cystic-Fibrosis-Foundation-Evidence-Based
  21. https://www.cff.org/medical-professionals/cf-diagnosis-clinical-care-guidelines
  22. https://pmc.ncbi.nlm.nih.gov/articles/PMC1320177/
  23. https://ojrd.biomedcentral.com/articles/10.1186/s13023-024-03506-1
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC11487898/
  25. https://journals.lww.com/ajpn/fulltext/2020/03010/an_unusual_cause_for_hypokalemic_metabolic.9.aspx
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC3922296/
  27. https://academic.oup.com/labmed/article/43/2/1/2504943
  28. https://pmc.ncbi.nlm.nih.gov/articles/PMC8349375/
  29. https://www.atsjournals.org/doi/full/10.1164/rccm.201606-1286ED
  30. https://emedicine.medscape.com/article/924100-workup
  31. https://www.nature.com/articles/s41551-022-00916-z
  32. https://www.mdpi.com/2224-2708/13/4/40
  33. https://www.vcuhealth.org/news/sweat-sensors-could-help-monitor-patients-with-liver-disease-new-study-finds/
  34. https://pmc.ncbi.nlm.nih.gov/articles/PMC12314300/
  35. https://doi.org/10.11613/BM.2022.010501
  36. https://www.jpeds.com/article/S0022-3476(17)30067-8/fulltext
  37. https://www.texaschildrens.org/content/conditions/sweat-test
  38. https://www.childrenshospital.org/treatments/sweat-testing
  39. https://www.jpeds.com/article/S0022-3476(10)00762-1/fulltext
  40. https://sflung.com/wp-content/uploads/2025/08/Diagnostic-Sweat-Testing-Guidelines.pdf
  41. https://pubmed.ncbi.nlm.nih.gov/15880420/
  42. https://pmc.ncbi.nlm.nih.gov/articles/PMC8129525/
  43. https://www.frontiersin.org/journals/pediatrics/articles/10.3389/fped.2017.00222/full
  44. https://www.exeterlaboratory.com/images/sweat-guideline-v2-1.pdf
  45. https://www.sciencedirect.com/science/article/abs/pii/S0022347696700343
  46. https://resources.schn.health.nsw.gov.au/policies/policies/pdf/2013-1001.pdf
  47. https://pubmed.ncbi.nlm.nih.gov/29611353/
  48. https://meridian.allenpress.com/aplm/article/125/11/1420/452871/Assessment-of-Sweat-Testing-Practices-for-the
Add your contribution
Related Hubs
User Avatar
No comments yet.